Progress in Rett Syndrome: from discovery to clinical trials

about

Breathing abnormalities in animal models of Rett syndrome a female neurogenetic disorder.Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome.

P2860

Q39019145-899042C5-AD24-4F9B-A9B0-A4E3773E4BFB Q54943580-66B6D262-B83B-4AF3-999D-B7480A6FC312

P2860

Progress in Rett Syndrome: from discovery to clinical trials

Item

http://www.wikidata.org/entity/Q37218356

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Progress in Rett Syndrome: from discovery to clinical trials

@en

Progress in Rett Syndrome: from discovery to clinical trials.

@nl

type

Item

label

Progress in Rett Syndrome: from discovery to clinical trials

@en

Progress in Rett Syndrome: from discovery to clinical trials.

@nl

prefLabel

Progress in Rett Syndrome: from discovery to clinical trials

@en

Progress in Rett Syndrome: from discovery to clinical trials.

@nl

P1476

Progress in Rett Syndrome: from discovery to clinical trials

@en

P2093

Alan K Percy

http://www.w3.org/2001/XMLSchema#string

P2860

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

Rett syndrome: revised diagnostic criteria and nomenclature

Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2

Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA

Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome

Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice

The solution structure of the domain from MeCP2 that binds to methylated DNA

MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin

Reversal of neurological defects in a mouse model of Rett syndrome

P2888

s10354-016-0491-9

P304

325-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10354-016-0491-9

http://www.w3.org/2001/XMLSchema#string

P433

11-12

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27491553

http://www.w3.org/2001/XMLSchema#string

P932

5005392

http://www.w3.org/2001/XMLSchema#string

Progress in Rett Syndrome: from discovery to clinical trials

about

P2860

P2860

Progress in Rett Syndrome: from discovery to clinical trials

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932